EHS has completed the new on line Introduction to Laboratory Safety Course, this course replaces the monthly classroom offerings and removes any remaining barriers to full compliance by anyone working in a DC laboratory specifically undergraduates with class conflicts.
Radiation Safety Classroom Training - Contact EHS 646-1762
The Dartmouth College Institutional Biosafety Committee - Subcommittee for Clinical Gene Transfer (IBC-SCGT) is a multidisciplinary committee charged with the review of clinical protocols involving gene transfer as defined in the NIH Guidelines For Research Involving Recombinant Or Synthetic Nucleic Acid Molecules, March 2013. This will include, (1) review of the scientific principles and objectives of the clinical gene transfer protocol; (2) review of the protocol for concerns of the safety of personnel, the community, and the environment and (3) review to determine whether all appropriate requirements as stated in the NIH Guidelines have been fulfilled prior to initiation of the protocol. The sub-committee has the authority to approve, require modifications in, or disapprove all research activities that fall within its jurisdiction. All new clinical gene transfer protocols and amendments to existing protocols are subject to review by the sub-committee. This sub-committee reports to the Dartmouth Institutional Biosafety Committee and the Committee for Protection of Human Subjects (CPHS), the IRB at Dartmouth.
Refer to the IBC-SCGT ByLaws to learn more about the subcommittee review and oversight process and the scope of the committee's oversight.
Refer the SOP for Protocol Submission as a guide for investigators to compile all required information for IBC-SCGT review. This can be used as a checklist for protocol documentation and throughout the protocol review process.
Refer to the Local SOP and complete all required information, then submit this SOP, along with all other protocol documentation, for IBC-SCGT review. This is a required document by the IBC-SCGT to analyze the risks associated with the potential study hazards.
Refer to the NIH Guidelines for the regulations regarding protocol submission (Appendix M) to the Recombinant DNA Advisory Committee (RAC), as well as the responsibilities for all primary investigators.
Deborah A. Hogan, Ph.D., IBC Chair/Microbiology and Immunology
Lionel Lewis, BCH, MD, IBC-SCGT Chair/Medicine/Pharmacology & Toxicology
Brian J. O'Shea, Ph.D., Biological Safety Officer, Environmental Health & Safety
Maureen O'Leary, Ph.D., MBA, CBSP, Director, Environmental Health and Safety
Elizabeth Bankert, MA, Assistant Provost/Human Subjects Protection Official
Rebecca Rogers, NCCC, Office of Clinical Research
Dianne Ferris, Human Research Analyst, CPHS
Douglas D. Parr, Pharm.D, Investigational Pharmacy
Richard J. Powell, MD, Chief, Section of Vascular Surgery
Brent Berwin, Ph.D., IBC Member, Microbiology/Immunology
Last Updated: 9/4/13